MarketCap
Facebook
X
Telegram
Inhibikase Therapeutics Income Statement 2025-2011 | IKT
Brief overview of financial performance at Inhibikase Therapeutics
This overview is based on financial performance over the past five years. The revenue attributed to Inhibikase Therapeutics moved from $4 million to $261 thousand between the two endpoints. Overall revenue changed by −93.6%, equal to an annualized rate of about −42.2%. Revenue ended the period on a sustained downward trend.
Over the period, EBITDA shifted from −$2.1 million to −$19.9 million, a change of −838.3%. Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −52.5% to −7643.9%. The margin contraction indicates weaker operating efficiency.
The net financial result changed from −$2.2 million to −$19 million. The period ended with a larger loss than it began with.
Conclusion
The results contain several connected negative signals. The overall view is constrained by limited operating profitability, declining net profitability and a softer top-line trend. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Inhibikase Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
160 M | 38.7 M | 13.9 M | 3.25 M | 19.3 M | 54.7 M | - | - | - | - | - | - | - | - | - |
Shares |
98.3 M | 23.7 M | 6.03 M | 4.22 M | 18.2 M | 8.21 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
1.63 | 1.63 | 2.3 | 0.77 | 1.06 | 6.7 | - | - | - | - | - | - | - | - | - |
Net Income |
-48.3 M | -27.5 M | -19 M | -18.1 M | -14.8 M | -2.85 M | -5.72 M | -2.15 M | - | - | - | - | - | - | - |
Revenue |
- | - | 261 K | 123 K | 3.1 M | 698 K | 1.12 M | 4.04 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 698 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-52 M | -28.6 M | -20.1 M | -18.1 M | -14.8 M | -2.82 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
3.72 M | 1.07 M | 1.06 M | 74.5 K | -19.9 K | 29.4 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-51.9 M | -28.6 M | -19.9 M | -18.1 M | -14.8 M | - | -5.7 M | -2.12 M | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 3.52 M | 6.82 M | 6.16 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
23.6 M | 11.4 M | 6.73 M | 6.22 M | 6.51 M | 2.62 M | 4.27 M | 2.52 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Inhibikase Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
172 M | 90.1 M | 90 M | 89.5 M | 69.4 M | 8.88 M | 7.54 M | 6.34 M | 6.19 M | 5.34 M | 5.23 M | 4.59 M | 4.22 M | 4.22 M | 4.22 M | 25.2 M | 25.2 M | 25.1 M | 12.2 M | 10.1 M | 10.1 M | 8.2 M | 8.18 M | 8.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-16.4 M | -11.9 M | -9.92 M | -13.7 M | - | -5.78 M | -4.96 M | -4.65 M | - | -4.6 M | -5.78 M | -4.48 M | - | -4.49 M | -4.64 M | -4.64 M | - | -4.47 M | -2.64 M | -2.64 M | - | -671 K | -422 K | -547 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | 79.6 K | 116 K | 64.5 K | - | 7.29 K | 6.55 K | 46 K | - | 328 K | 1.36 M | 1.41 M | - | 37.7 K | 220 K | 271 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-17.8 M | -12.8 M | -10.8 M | -14.6 M | - | -5.83 M | -5.05 M | -4.78 M | - | -4.77 M | -6.2 M | -4.71 M | - | -4.51 M | -4.64 M | -4.64 M | - | -4.47 M | -2.63 M | -2.63 M | - | -664 K | -414 K | -540 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.46 M | 838 K | 917 K | 919 K | - | 49.4 K | 90.9 K | 133 K | - | 174 K | 424 K | 237 K | - | 18.5 K | 5 | -5 | - | 157 | 7.81 K | 11.8 K | - | 6.89 K | 7.95 K | 7.42 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-17.8 M | -12.7 M | -10.8 M | -14.6 M | - | -5.82 M | -5.04 M | -4.78 M | - | -4.76 M | -6.04 M | -4.71 M | - | -4.51 M | -4.64 M | -4.64 M | - | -4.47 M | -2.63 M | -2.63 M | - | -664 K | -414 K | -540 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.38 M | 5.61 M | 5.92 M | 5.25 M | - | 1.64 M | 1.97 M | 2.03 M | - | 1.62 M | 1.78 M | 1.93 M | - | 1.54 M | 1.66 M | 1.67 M | - | 1.64 M | 1.61 M | 1.6 M | - | 581 K | 370 K | 528 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Inhibikase Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
